AstraZeneca PLC
http://www.astrazeneca.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AstraZeneca PLC
As Biopharma Seeks Broader IRA Orphan Exclusion, Study Urges Boosting Savings By Eliminating It
Research takes deep dive into the implications around exempting certain orphan drugs that may qualify for the Inflation Reduction Act’s Medicare price negotiation program, including the effect of the exemption on Medicare spending and the revenue potential of those drugs.
Novartis’s Fabhalta Reaches First Stop On Regulatory Journey With PNH Nod
Novartis envisions the drug, the first oral monotherapy for PNH, as a “pipeline in a pill” that could see $3bn in peak sales, with a Phase III readout in IgAN in October and one in C3G expected this month.
AstraZeneca Likes What Chinese Innovation Has To Offer
Chinese drugmakers’ “ability to move quicker at pace and with purpose” than counterparts in the US, Europe and other parts of the world underlies increasing deal activity with big pharmas, AstraZeneca’s BD chief Shaun Grady tells Scrip.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alexion Pharmaceuticals Inc.
- Almirall Sofotec
- AlphaCore Pharma
- Amplimmune, Inc.
- Ardea Biosciences, Inc.
- Arrow Therapeutics
- Aviron
- Cellective Therapeutics, Inc.
- Definiens
- IntraBiotics Pharmaceuticals, Inc.
- KuDOS Pharmaceuticals Ltd.
- Medimmune
- Novexel
- Neogene Therapeutics, Inc.
- Omthera Pharmaceuticals
- Pearl Therapeutics
- Spirogen Ltd.
- TeneoTwo, Inc.
- U.S. Bioscience
- Acerta Pharma
- ZS Pharma
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice